Novel biomimetic nanoparticle

Systemically administered antibody drugs, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), often lose efficacy upon reaching target organs due to a combination of physiological barriers, pharmacokinetic limitations, and molecular mechanisms of resistance. While designed to be "magic bullets," typically less than 1–2% of administered antibodies successfully accumulate at the target site. Presence of unstable linker, low tumour penetration, off-target uptake, antigen shedding, and resistance confer low efficacy to antibody-drug conjugate. Nanotechnology significantly improves the therapeutic efficacy of antibody drugs administered systemically by overcoming challenges related to stability, targeting, and immunogenicity. By encapsulating antibodies within or conjugating them to nanoparticles (NPs), these therapies are protected from premature degradation, achieve higher concentrations at target organs, and maintain their functional integrity. Consequently, there is a need for new approaches to extend nanoparticle residence time in vivo through particle surface modifications to circumvent macrophage uptake and systemic clearance. The present invention relates to a novel biomimetic nanoparticle mixture for encapsulating nanoparticles with human cell membrane, in particular, cancer cell membranes. The mixture comprises nanoparticles, as well as click chemistry-based linkers.